The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
 
Carlos A. Gomez-Roca
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche/Genentech
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Ellipses Pharma (Inst); Luzsana Biotechnology (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Cytovation (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Kling Biotherapeutics (Inst); Lilly (Inst); Luzsana Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eelke Hiddo Gort
Consulting or Advisory Role - Merck
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Hilde A.M. De Winter
Employment - Molecular Partners
Stock and Other Ownership Interests - Argenx; Molecular Partners; Sanofi
 
Elena Fernandez
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners; Roche
 
Vaia Stavropoulou
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Nina Stojcheva
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Paul Baverel
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Jennifer Krieg
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Kyriaki Ioannou
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Ana Maria Florescu
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Patrick Mossi
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Lea Hoenig
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Bruno Baud-Berthier
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Vladimir Kirkin
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Anne Goubier
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Philippe Legenne
Employment - Molecular Partners
Stock and Other Ownership Interests - Amgen; Amgen
Honoraria - Johnson & Johnson/Janssen (I)
Travel, Accommodations, Expenses - Molecular Partners
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche